BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spiller RC. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol. 2011;11:68-74. [PMID: 21398180 DOI: 10.1016/j.coph.2011.02.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Wood JD. Neuropathophysiology of the Irritable Bowel Syndrome. Physiology of the Gastrointestinal Tract. Elsevier; 2018. pp. 1643-68. [DOI: 10.1016/b978-0-12-809954-4.00067-0] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gazouli M, Wouters MM, Kapur-pojskić L, Bengtson M, Friedman E, Nikčević G, Demetriou CA, Mulak A, Santos J, Niesler B. Lessons learned — resolving the enigma of genetic factors in IBS. Nat Rev Gastroenterol Hepatol 2016;13:77-87. [DOI: 10.1038/nrgastro.2015.206] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
3 Rao S, Weber HC. New treatment targets for the management of irritable bowel syndrome. Current Opinion in Endocrinology, Diabetes & Obesity 2014;21:9-14. [DOI: 10.1097/med.0000000000000034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Barbaro MR, Di Sabatino A, Cremon C, Giuffrida P, Fiorentino M, Altimari A, Bellacosa L, Stanghellini V, Barbara G. Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016;310:G439-47. [DOI: 10.1152/ajpgi.00368.2015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
5 Yu B, Zhu X, Yang X, Jin L, Xu J, Ma T, Yang H. Plumbagin Prevents Secretory Diarrhea by Inhibiting CaCC and CFTR Channel Activities. Front Pharmacol 2019;10:1181. [PMID: 31649543 DOI: 10.3389/fphar.2019.01181] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Itagaki R, Koda K, Yamazaki M, Shuto K, Kosugi C, Hirano A, Arimitsu H, Shiragami R, Yoshimura Y, Suzuki M. Serotonin (5-HT3) receptor antagonists for the reduction of symptoms of low anterior resection syndrome. Clin Exp Gastroenterol 2014;7:47-52. [PMID: 24648748 DOI: 10.2147/CEG.S55410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
7 Barbara G. Revival of 5-HT3 antagonism as treatment of IBS-D? Gut. 2014;63:1530-1532. [PMID: 24465028 DOI: 10.1136/gutjnl-2013-306457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
8 Kawahara Y, Mitsui K, Niwa T, Morimoto N, Kawaharada S, Katsumata S. Translocator protein 18kDa antagonist ameliorates stress-induced stool abnormality and abdominal pain in rodent stress models. Neurogastroenterol Motil 2018;30:e13425. [PMID: 30069991 DOI: 10.1111/nmo.13425] [Reference Citation Analysis]
9 Hoyer D. Targeting the 5-HT system: Potential side effects. Neuropharmacology 2020;179:108233. [PMID: 32805212 DOI: 10.1016/j.neuropharm.2020.108233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018;60:213-222. [PMID: 30257542 DOI: 10.23736/s0031-0808.18.03541-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
11 Al-Saffar A, Takemi S, Saaed HK, Sakata I, Sakai T. Utility of animal gastrointestinal motility and transit models in functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2019;40-41:101633. [PMID: 31594654 DOI: 10.1016/j.bpg.2019.101633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 John ES, Chokhavatia S. Targeting Small Bowel Receptors to Treat Constipation and Diarrhea. Curr Gastroenterol Rep 2017;19:31. [PMID: 28593453 DOI: 10.1007/s11894-017-0573-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Chiba T, Yamamoto K, Sato S, Suzuki K. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2013;6:123-128. [PMID: 23922505 DOI: 10.2147/ceg.s32721] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
14 Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin Gastroenterol Hepatol. 2017;15:182-193.e3. [PMID: 27496381 DOI: 10.1016/j.cgh.2016.07.028] [Cited by in Crossref: 70] [Cited by in F6Publishing: 48] [Article Influence: 11.7] [Reference Citation Analysis]
15 Spasov AA, Yakovlev DS. 5-HT3 Receptors as Targets for Biologically Active Compounds (Review). Pharm Chem J 2013;47:399-404. [DOI: 10.1007/s11094-013-0968-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Liu Y, Zhao J, Fan X, Guo W. Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders. Front Psychiatry 2019;10:286. [PMID: 31178761 DOI: 10.3389/fpsyt.2019.00286] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
17 Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, Lin L. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0172846. [PMID: 28291778 DOI: 10.1371/journal.pone.0172846] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
18 Moore NA, Sargent BJ, Manning DD, Guzzo PR. Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D. ACS Chem Neurosci. 2013;4:43-47. [PMID: 23342199 DOI: 10.1021/cn300166c] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
19 Basak S, Gicheru Y, Samanta A, Molugu SK, Huang W, Fuente M, Hughes T, Taylor DJ, Nieman MT, Moiseenkova-Bell V, Chakrapani S. Cryo-EM structure of 5-HT3A receptor in its resting conformation. Nat Commun 2018;9:514. [PMID: 29410406 DOI: 10.1038/s41467-018-02997-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 16.5] [Reference Citation Analysis]
20 Cao Z, Zhu J, Wang L, Liao S, Tang Y. A Synthesis of Multifunctionalized Indoles from [3 + 2] Annulation of 2-Bromocyclopropenes with Anilines. Org Lett 2019;21:4097-100. [DOI: 10.1021/acs.orglett.9b01276] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
21 Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: A microbiome-gut-brain axis disorder? World J Gastroenterol 2014; 20(39): 14105-14125 [PMID: 25339800 DOI: 10.3748/wjg.v20.i39.14105] [Cited by in CrossRef: 178] [Cited by in F6Publishing: 146] [Article Influence: 22.3] [Reference Citation Analysis]
22 Feng CC, Yan XJ, Chen X, Wang EM, Liu Q, Zhang LY, Chen J, Fang JY, Chen SL. Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. Pain 2014;155:1591-604. [PMID: 24813296 DOI: 10.1016/j.pain.2014.05.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
23 Dulskas A, Smolskas E, Kildusiene I, Samalavicius NE. Treatment possibilities for low anterior resection syndrome: a review of the literature. Int J Colorectal Dis 2018;33:251-60. [PMID: 29313107 DOI: 10.1007/s00384-017-2954-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
24 Wood JD. Pathophysiology Underlying the Irritable Bowel Syndrome. Physiology of the Gastrointestinal Tract. Elsevier; 2012. pp. 2157-81. [DOI: 10.1016/b978-0-12-382026-6.00081-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Juza R, Vlcek P, Mezeiova E, Musilek K, Soukup O, Korabecny J. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev 2020;40:1593-678. [PMID: 32115745 DOI: 10.1002/med.21666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
26 Mitsui K, Niwa T, Kawahara Y, Morimoto N, Ohmoto K, Kato M, Yamaura Y, Yoshimoto N, Suna H, Katsumata S. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology 2015;99:51-66. [DOI: 10.1016/j.neuropharm.2015.07.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
27 Jun SE, Kohen R, Cain KC, Jarrett ME, Heitkemper MM. TPH gene polymorphisms are associated with disease perception and quality of life in women with irritable bowel syndrome. Biol Res Nurs 2014;16:95-104. [PMID: 23172723 DOI: 10.1177/1099800412466694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
28 Basak S, Kumar A, Ramsey S, Gibbs E, Kapoor A, Filizola M, Chakrapani S. High-resolution structures of multiple 5-HT3AR-setron complexes reveal a novel mechanism of competitive inhibition. Elife 2020;9:e57870. [PMID: 33063666 DOI: 10.7554/eLife.57870] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
29 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 2021;73:310-520. [PMID: 33370241 DOI: 10.1124/pr.118.015552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
30 Martinucci I, Blandizzi C, de Bortoli N, Bellini M, Antonioli L, Tuccori M, Fornai M, Marchi S, Colucci R. Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. Pharmacogenomics 2015;16:523-39. [PMID: 25916523 DOI: 10.2217/pgs.15.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
31 Kalkman HO, Feuerbach D. Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders. Cell Mol Life Sci 2016;73:2511-30. [PMID: 26979166 DOI: 10.1007/s00018-016-2175-4] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 15.7] [Reference Citation Analysis]
32 Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12:953-959.e4. [PMID: 24315882 DOI: 10.1016/j.cgh.2013.11.024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
33 Liao XJ, Mao WM, Wang Q, Yang GG, Wu WJ, Shao SX. MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome. Biochem Biophys Res Commun. 2016;469:288-293. [PMID: 26631964 DOI: 10.1016/j.bbrc.2015.11.102] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
34 Fu R, Chen M, Chen Y, Mao G, Liu S. Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome. Exp Ther Med. 2019;17:3077-3082. [PMID: 30936979 DOI: 10.3892/etm.2019.7297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Voß U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol. 2012;473-497. [PMID: 23027463 DOI: 10.1007/978-3-642-30726-3_21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
36 Roach G, Heath Wallace R, Cameron A, Emrah Ozel R, Hongay CF, Baral R, Andreescu S, Wallace KN. Loss of ascl1a prevents secretory cell differentiation within the zebrafish intestinal epithelium resulting in a loss of distal intestinal motility. Dev Biol 2013;376:171-86. [PMID: 23353550 DOI: 10.1016/j.ydbio.2013.01.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
37 Ryoo SB, Park JW, Lee DW, Lee MA, Kwon YH, Kim MJ, Moon SH, Jeong SY, Park KJ. Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer. Br J Surg 2021;108:644-51. [PMID: 33982068 DOI: 10.1093/bjs/znab071] [Reference Citation Analysis]
38 Verheij MH, Thompson AJ, van Muijlwijk-Koezen JE, Lummis SC, Leurs R, de Esch IJ. Design, synthesis, and structure-activity relationships of highly potent 5-HT₃ receptor ligands. J Med Chem 2012;55:8603-14. [PMID: 23006041 DOI: 10.1021/jm300801u] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
39 Zhan K, Zheng H, Li J, Wu H, Qin S, Luo L, Huang S. Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome. Biomed Res Int 2020;2020:3828249. [PMID: 33274207 DOI: 10.1155/2020/3828249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Shi Y, Chen YH, Yin XJ, Wang AQ, Chen XK, Lu JH, Ji R, Bao CH, Sun J, Zhao JM, Wu HG. Electroacupuncture versus Moxibustion for Irritable Bowel Syndrome: A Randomized, Parallel-Controlled Trial. Evid Based Complement Alternat Med 2015;2015:361786. [PMID: 26294923 DOI: 10.1155/2015/361786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ozel RE, Wallace KN, Andreescu S. Alterations of intestinal serotonin following nanoparticle exposure in embryonic zebrafish. Environ Sci Nano 2014;2014:27-36. [PMID: 24639893 DOI: 10.1039/C3EN00001J] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
42 Lee KJ. Pharmacologic Agents for Chronic Diarrhea. Intest Res 2015;13:306-12. [PMID: 26576135 DOI: 10.5217/ir.2015.13.4.306] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
43 Nocera F, Angehrn F, von Flüe M, Steinemann DC. Optimising functional outcomes in rectal cancer surgery. Langenbecks Arch Surg 2021;406:233-50. [PMID: 32712705 DOI: 10.1007/s00423-020-01937-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
44 Basak S, Gicheru Y, Kapoor A, Mayer ML, Filizola M, Chakrapani S. Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor. Nat Commun 2019;10:3225. [PMID: 31324772 DOI: 10.1038/s41467-019-11142-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
45 Wald A. Irritable bowel syndrome--diarrhoea. Best Pract Res Clin Gastroenterol. 2012;26:573-580. [PMID: 23384803 DOI: 10.1016/j.bpg.2012.11.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]